Boston Scientific Corp. shares plunged in morning trade after company executives used a high-profile investor appearance to reduce near-term growth expectations, surprising investors who had anticipated that the recent growth slowdown was already reflected in the stock.
At roughly 8:00 a.m. ET, CEO Mike Mahoney and Chief Medical Officer Dr. Janar Sathananthan took part in a 50-minute question-and-answer session at Bernstein’s 42nd Annual Strategic Decisions Conference. During that event management revised full-year organic growth guidance to a range of 6.5% to 8% and set second-quarter organic growth at 5% to 7%.
The updated outlook accompanied a disclosure that WATCHMAN procedure volumes fell for the first time beginning in February. Executives said that while demand for concomitant procedures remained robust, there had been a notable slowdown in standalone WATCHMAN cases, which was one of the contributors to the guidance revision.
Analyst sentiment had already shifted against the company prior to the conference remarks, and the guidance reset intensified that trend. Daiwa downgraded Boston Scientific to Neutral from Outperform, trimming its price target to $60 from $83. Bank of America reduced its price target to $68 from $105 but retained a Buy rating. Management singled out weakness in the electrophysiology (EP), WATCHMAN, and Urology businesses as the areas contributing most to the guidance reduction.
In explaining the change, company leadership said the guidance revision reflects "unanticipated headwinds and changing business patterns." The management commentary also highlighted a set of risks they see for the business going forward, including potential competitive share erosion in EP, constraints on hospital capacity and reimbursement that could affect WATCHMAN demand, and margin pressure from tariffs.
Market conditions offered little support on the day of the update. The S&P 500 and NASDAQ were largely unchanged while the Dow Jones Industrial Average posted only marginal gains. Boston Scientific had already been pressured over the prior 30 days by investor worries about slowing growth in its EP and WATCHMAN franchises, and the conference guidance cut accelerated the selling.
Shares of BSX reached an intraday low of $50.75, marking a new 52-week low and underscoring the intensity of the decline relative to peers in the medical device sector. In morning trading the stock dropped 10.3%, reflecting the immediate market reaction to the guidance revision and accompanying analyst adjustments.
Observers point to a confluence of factors that amplified the selloff: a live guidance reduction at a widely attended investor conference, an existing downtrend in the stock, and multiple analyst price-target cuts. On the company’s recent earnings call, CEO Mahoney had said the guidance change was driven by "unanticipated headwinds and changing business patterns," language that management reiterated at the Bernstein event.
Despite the sharp near-term reaction, the majority of analysts on Wall Street continue to maintain bullish long-term ratings on the stock, viewing the guidance adjustment as a reset rather than a fundamental breakdown in the enterprise. That split between short-term market sentiment and longer-term analyst views contributed to the volatility observed in the shares following the conference remarks.
Context and implications
The guidance reduction and the cited weakness in key product areas touch on several parts of the healthcare sector and the medical device subsector specifically. Hospital operations, reimbursement dynamics, and competitive positioning in electrophysiology and WATCHMAN procedures were all identified by management as factors affecting near-term performance.
Management comments, analyst actions, and the market’s immediate response combined to produce a pronounced decline in the stock price and a reset of investor expectations for the near term.